国外主要自发呈报系统数据库分析及应用

doi:10.19803/j.1672-8629.2021.12.09

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (12): 1144-1147.
DOI: 10.19803/j.1672-8629.2021.12.09

国外主要自发呈报系统数据库分析及应用

迟立杰^1,2, 陈晨鑫¹, 郑轶¹, 韦连慧¹, 陈枭¹, 郭志坚¹, 郭晓晶¹, 贺佳¹, 叶小飞^1,*

¹海军军医大学卫勤系卫生统计学教研室,上海 200433;
²解放军总医院海南医院卫勤部,海南三亚 572000

收稿日期:2020-10-31 出版日期:2021-12-15 发布日期:2021-12-16
通讯作者: ^*叶小飞,男,副教授,药物流行病学。 E-mail：yexiaofei@smmu.edu.cn
作者简介:迟立杰,男,硕士,药物流行病学。
基金资助:
国家自然科学基金资助项目（82073671）; 上海市自然科学基金资助项目（18ZR1449500）; 上海市第四轮公共卫生三年行动计划重点学科建设项目循证公共卫生与卫生经济学(15GWZK0901); 上海市卫计委优秀青年医学人才培养计划（2018YQ47）; 上海市公共卫生学科带头人（GWV-10.2-XD22）; 上海市公共卫生优青计划（GWV-10.2-YQ33）

Applications of International Spontaneous Reporting System Databases

CHI Lijie^1,2, CHEN Chenxin¹, ZHENG Yi¹, WEI Lianhui¹, CHEN Xiao¹, GUO Zhijian¹, GUO Xiaojing¹, HE Jia¹, YE Xiaofei^1,*

¹Department of Health Statistics, Faculty of Health Service, Naval Medical University, Shanghai 200433, China;
²Department of Health Service, Hainan Hospital of PLA General Hospital, Sanya Hainan 572000, China

Received:2020-10-31 Online:2021-12-15 Published:2021-12-16

摘要/Abstract

摘要： 目的介绍目前国外主要药品不良反应自发呈报系统世界卫生组织个案安全性病例报告数据库（VigiBase）、美国食品药品监督管理局不良事件报告系统（FAERS）、欧洲药品管理局不良反应数据库（EudraVigilance）应用现状。方法查阅国外主要自发呈报系统数据库相关网站,系统检索中外有关利用自发呈报系统文章并进行综述。从数据库的数据格式、利用数据库的权限、数据质量控制等方面对自发呈报系统数据库进行介绍,并对数据库的应用现状举例分析。结果国外自发呈报系统数据库数据可公开下载或在一定条件下获取,目前研究者利用国外自发呈报系统数据库已开展较多研究。结论自发呈报系统数据库对开展上市后安全性监测有较大价值,我国自发呈报系统数据库在数据共享方面可借鉴国外做法。

关键词: 药品不良反应, 自发呈报系统, 数据库, 国外

Abstract: Objective To outline the current applications of main international spontaneous reporting systems of ADR, including Vigibase, FAERS and EudraVigilance.Methods The websites of major foreign spontaneous reporting systems were searched and articles about the use of spontaneous reporting systems were retrieved. The data format of these databases, accessibility to them, data quality control and the applications of the databases were illustrated with examples. Results The databases of foreign spontaneous reporting systems can be downloaded publicly or obtained under certain conditions. A number of research programs have been conducted based on spontaneous reporting systems.Conclusion The spontaneous reporting system is of great value for post-marketing safety monitoring and China's spontaneous reporting system database can learn from foreign practices in data sharing.

Key words: adverse drug reaction, spontaneous reporting system, database, international

中图分类号:

R971.1

迟立杰, 陈晨鑫, 郑轶, 韦连慧, 陈枭, 郭志坚, 郭晓晶, 贺佳, 叶小飞. 国外主要自发呈报系统数据库分析及应用[J]. 中国药物警戒, 2021, 18(12): 1144-1147.

CHI Lijie, CHEN Chenxin, ZHENG Yi, WEI Lianhui, CHEN Xiao, GUO Zhijian, GUO Xiaojing, HE Jia, YE Xiaofei. Applications of International Spontaneous Reporting System Databases[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1144-1147.

参考文献

[1] UMC. VigiBase: signalling harm and pointing to safer use[EB/OL]. (2020-09-16)[2020-10-18]. https://www.who-umc.org/vigibase/vigibase/vigibase-signalling-harm-and-pointing-to-safer-use/.
[2] UMC. VigiBase FAQs[EB/OL]. (2020-09-16)[2020-10-18]. https://www.who-umc.org/vigibase/vigibase/know-more-about-vigibase/.
[3] UMC. Custom Searches[EB/OL]. (2020-09-16)[2020-10-18]. https://www.who-umc.org/vigibase/services/vigibase-custom-searches/.
[4] UMC. VigiBase extract case level[EB/OL]. (2020-09-16)[2020-10-18]. https://www.who-umc.org/vigibase/services/.
[5] UMC. What is WHO-ART? [EB/OL]. (2020-09-17)[2020-10-18]. https://www.who-umc.org/vigibase/services/learn-more-about-who-art/.
[6] U.S Food&Drug Administration. FDA adverse event reporting system (FAERS): latest quarterly data files[EB/OL]. (2018-08-03)[2020-10-18]. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files.
[7] U.S Food&Drug Administration. FDA adverse event reporting system (FAERS) quarterly data extract files[EB/OL]. (2018-08-04)[2020-10-18]. https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
[8] European Medicines Agency.Access to EudraVigilance data[EB/OL]. [2020-10-18].https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/access-eudravigilance-data.
[9] UMC. VigiBase FAQs[EB/OL]. (2020-09-16)[2020-12-03]. https://www.who-umc.org/vigibase/vigibase/know-more-about-vigibase/.
[10] U.S Food&Drug Administration. Questions and Answers on FDA's Adverse Event Reporting System (FAERS) [EB/OL]. (2018-06-04)[2020-12-03]. https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers.
[11] U.S Food&Drug Administration. FDA adverse event reporting system (FAERS) electronic submissions FAQs[EB/OL]. (2020-03-03)[2020-12-03]. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-electronic-submissions.
[12] U.S Food&Drug Administration. FDA adverse event reporting system (FAERS): latest quarterly data files[EB/OL]. (2018-08-03)[2020-12-03]. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files.
[13] European Medicines Agency. Data on medicines (ISO IDMP standards): overview[EB/OL]. (2018-08-04)[2020-10-18]. https://www.ema.europa.eu/en/human-regulatory/overview/data-medicines-iso-idmp-standards-overview.
[14] Bai X, Lin X, Zeng K, et al.Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase[J]. Endocrine, 2020, 69: 670-681.
[15] Bai X, Chen X, Zheng KN, et al.Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study[J]. Endocrinol Invest, 2020, 43(10): 1473-1483.
[16] Wu B, Xiao GR, Luo M, et al.Data mining and safety analysis of drugs for novel coronavirus pneumonia treatment based on FAERS: α-Interferon[J]. Herald of Medicine(医药导报), 2020, 39(4): 492-497.
[17] Zhai YH, Ye XF, Hu FY, et al.Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system[J]. Journal for Immunotherapy of Cancer, 2019, 7(1): 286.
[18] Hu FY, Ye XF, Zhai YH, et al.Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019[J]. Immunotherapy, 2020, 12(7): 531-540.
[19] Ye XY, Hu FY, Zhai YH, et al.Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019[J]. Hematological Oncology, 2020, 38(4): 565-575.
[20] Ji HH, Tang XW, Dong Z, et al.Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS[J]. Clinical Drug Investigation, 2019, 39(3): 319-330.
[21] Meng L, Huang J, Jia YT, et al.Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system[J]. Int J Clin Pract, 2019, 73(5): e13331.
[22] Tian XJ, Jia YT, Wang KJ, et al.A quick data mining and analysis of lopinavir/ritonavir(LPV/r) adverse events based on Eudravigilanc[J]. Chinese Journal of New Drugs(中国新药杂志), 2020, 29(9): 1073-1080.

国外主要自发呈报系统数据库分析及应用

Applications of International Spontaneous Reporting System Databases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[3]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[4]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[5]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[6]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[7]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[8]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.